切换至 "中华医学电子期刊资源库"

中华产科急救电子杂志 ›› 2014, Vol. 03 ›› Issue (03) : 163 -167. doi: 10.3877/cma.j.issn.2095-3259.2014.03.003

所属专题: 文献

专家论坛

乙型肝炎孕期抗病毒治疗对母婴结局的影响
黄倩1, 刘慧姝1,()   
  1. 1. 510623 广州市妇女儿童医疗中心产科
  • 收稿日期:2014-06-25 出版日期:2014-08-18
  • 通信作者: 刘慧姝

Effects of antiretroviral therapy on pregnancy outcomes for hepatitis B patients

Qian Huang1, Huishu Liu1()   

  • Received:2014-06-25 Published:2014-08-18
  • Corresponding author: Huishu Liu
引用本文:

黄倩, 刘慧姝. 乙型肝炎孕期抗病毒治疗对母婴结局的影响[J]. 中华产科急救电子杂志, 2014, 03(03): 163-167.

Qian Huang, Huishu Liu. Effects of antiretroviral therapy on pregnancy outcomes for hepatitis B patients[J]. Chinese Journal of Obstetric Emergency(Electronic Edition), 2014, 03(03): 163-167.

乙型肝炎病毒感染的妇女孕期抗病毒治疗不仅在于疾病本身的治疗,还在于阻断宫内垂直传播。临床应重视孕期根据母体病毒载量及肝病的严重程度关注抗病毒时机和药物选择,以获得良好的妊娠结局。

Antiretroviral therapy for hepatitis B virus carrier during pregnancy may not only cure the disease, but also interrupt intrauterine transmission of hepatitis B virus. The patients during pregnancy should be emphasized, on the basis of maternal serum viral loads and severity of the liver disease, optimal antiviral therapy time and antiviral agents are chosen to achieve favorable pregnancy outcome.

[1]
WHO Publication. Hepatitis B vaccines: WHO position paper--recommendations[J]. Vaccine, 2010, 28(3):589-590.
[2]
Gentile I, Borgia G. Vertical transmission of hepatitis B virus: challenges and solutions[J]. Int J Womens Health, 2014, 10(6):605-611.
[3]
中华医学会传染病寄虫学会. 病毒性肝炎防治方案[J]. 中华传染病杂志,1995, 13(4):241.
[4]
Liaw YF, Sung JJ, Chow WC, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease [J]. N Engl J Med, 2004, 351(15):1521-1531.
[5]
马军,段芳龄. 亚洲太平洋地区慢性乙型肝炎处理的共识(2005年最新报告)[J]. 胃肠病学和肝病学杂志,2005, 14(5):436-439.
[6]
中华医学会肝病学分会、感染病学分会. 慢性乙型肝炎防治指南[J]. 中华肝脏病杂志,2005, 13(12):881-891.
[7]
Leung N. Chronic hepatitis B in Asian women of childbearing age[J]. Hepatol Int, 2009, 3 Suppl 1:24-31.
[8]
Hu Y, Ding YL, Yu L. The impact of intrahepatic cholestasis of pregnancy with hepatitis B virus infection on perinatal outcomes[J]. Ther Clin Risk Manag, 2014, 23(10):381-385.
[9]
Jonas MM. Hepatitis B and pregnancy: an underestimated issue[J]. Liver Int. 2009, 29 Suppl 1:133-139.
[10]
Sinha S, Kumar M. Pregnancy and chronic hepatitis B virus infection[J]. Hepatol Res, 2010, 40(1):31-48.
[11]
Tse KY, Ho LF, Lao T. The impact of maternal HBsAg carrier status on pregnancy outcomes: a case-control study[J]. J Hepatol, 2005, 43(5):771-775.
[12]
Giles ML, Audsley J, Lewin SR, et al. Kucers′ the use of antibiotics: a clinical review of antibacterial, antifungal and antiviral drugs[M]. 6th ed. London: Hodder Arnold, 2010:2545-2562.
[13]
Mandelbrot L, Peytavin G, Firtion G, et al. Maternal-fetal transfer and amniotic fluid accumulation of lamivudine in human immunodeficiency virus-infected pregnant women[J]. Am J Obstet Gynecol, 2001, 184(2):153-158.
[14]
But DY, Yuen M, Fung J, et al. Safety evaluation of telbivudine[J]. Expert Opin Drug Saf, 2010, 9(5):821-829.
[15]
Bridges EG, Selden JR, Luo S. Nonclinical safety profile of telbivudine, a novel potent antiviral agent for treatment of hepatitis B[J]. Antimicrob Agents Chemother, 2008, 52(7):2521-258.
[16]
European Association For The Study Of The Liver. EASL clinical practice guidelines: Management of chronic hepatitis B virus infection[J]. J Hepatol, 2012, 57(1):167-185.
[17]
张丽菊,王玲. 替比夫定对妊娠后期乙型肝炎病毒宫内感染的阻断作用[J]. 中华肝脏病杂志,2009, 17(8):561-563.
[18]
韩国荣,江红秀,王根菊,等. 替比夫定对乙型肝炎病毒高载量孕妇母婴传播的阻断效果及其安全性[J]. 中华肝脏病杂志,2012, 3, 20(3):201-205.
[19]
Han GR, Cao MK, Zhao W, et al. A prospective and open-label study for the efficacy and safety of telbivudine in pregnancy for the prevention of perinatal transmission of hepatitis B virus infection[J]. J Hepatol, 2011, 55(6):1215-1221.
[20]
Kim HY, Choi JY, Park CH, et al. Outcome after discontinuing antiviral agents during pregnancy in women infected with hepatitis B virus[J]. J Clin Virol, 2013, 56(4):299-305.
[21]
Keeffe EB, Zeuzem S, Koff RS, et al. Report of an international workshop: Roadmap for management of patients receiving oral therapy for chronic hepatitis B[J]. Clin Gastroenterol Hepatol, 2007, 5(8):890-897.
[22]
曹彦君,方芳,刘敏,等. 接受抗病毒治疗的乙型肝炎患者妊娠期耐药20例分析[J]. 药物不良反应杂志,2013, 15(2):69-72.
[23]
Shi Z, Yang Y, Ma L, et al. Lamivudine in late pregnancy to interrupt in utero transmission of hepatitis B virus: a systematic review and meta-analysis [J]. Obstet Gynecol, 2010, 116(1): 147-159.
[24]
van Zonneveld M, van Nunen AB, Niesters HG, et al. Lamivudine treatment during pregnancy to prevent perinatal transmission of hepatitis B virus infection [J]. J Viral Hepat, 2003, 10(4):294-297.
[25]
Xu WM, Cui YT, Wang L, et al. Lamivudine in late pregnancy to prevent perinatal transmission of hepatitis B virus infection: a multicentre, randomized, double-blind, placebo-controlled study[J]. J Viral Hepat, 2009, 16(2):94-103.
[26]
Celen MK, Mert D, Ay M, et al. Efficacy and safety of tenofovir disoproxil fumarate in pregnancy for the prevention of vertical transmission of HBV infection[J]. World J Gastroenterol, 2013, 19(48):9377-9382.
[27]
Greenup AJ, Tan PK, Nguyen V, et al. Efficacy and safety of tenofovir disoproxil fumarate in pregnancy to prevent perinatal transmission of hepatitis B virus[J]. J Hepatol, 2014, 61(3):502-507
[28]
Yi W, Liu M, Cai HD. Safety of lamivudine treatment for chronic hepatitis B in early pregnancy[J]. World J Gastroenterol, 2012, 18(45):6645-6650.
[29]
Fontana RJ. Side effects of long-term oral antiviral therapy for hepatitis B[J]. Hepatology, 2009, 49(5 Suppl):S185-S195.
[30]
中华医学会肝病学分会,中华医学会感染病学分会. 慢性乙型肝炎防治指南(2010年版) [J]. 中华肝脏病杂志,2011, 19(1):13-24.
[31]
亚太肝病学会慢性乙型肝炎治疗共识工作组. 亚太地区慢性乙型肝炎治疗共识(2012最新版) [J]. 临床肝胆病杂志,2012, 28(8):1-21.
[1] 危玲, 李会, 陈奕. 孕产妇产超广谱β-内酰胺酶的肠杆菌定植/感染与母婴传播研究现状[J]. 中华妇幼临床医学杂志(电子版), 2023, 19(05): 517-521.
[2] 马娟, 唐仕芳, 刘慧敏, 张娅琴, 邓义娟, 汪丽, 李力. 《乙型肝炎病毒母婴传播预防临床指南(2020)》更新要点解读[J]. 中华妇幼临床医学杂志(电子版), 2021, 17(05): 516-526.
[3] 张小曼, 马筱秋, 许正锯, 张纯瑜, 何彩婷. 乙型肝炎病毒逆转录酶区耐药突变对血清乙型肝炎病毒表面抗原水平的影响[J]. 中华实验和临床感染病杂志(电子版), 2023, 17(05): 324-332.
[4] 朱晓红, 周诗梦, 朱晓霞, 邹美银. 壳聚糖修饰的聚乳酸-羟基乙酸共聚物纳米颗粒在控制释放抗人类免疫缺陷病毒药物传递中的应用[J]. 中华实验和临床感染病杂志(电子版), 2023, 17(02): 125-132.
[5] 全敏, 闫改琴, 邢卉春. 可溶性Fas水平在慢性乙型肝炎患者抗病毒应答不佳优化治疗中的变化[J]. 中华实验和临床感染病杂志(电子版), 2023, 17(01): 16-23.
[6] 谢芳, 熊熙, 姚传霞, 孙浩男, 李平, 汪茂荣. 聚乙二醇化干扰素α-2b联合核苷(酸)类似物治疗低水平乙型肝炎病毒表面抗原慢性乙型肝炎患者的临床疗效及影响因素[J]. 中华实验和临床感染病杂志(电子版), 2022, 16(04): 247-253.
[7] 高祥, 赵成军, 胡世宏. 年龄-胆红素-国际标准化比率-肌酐评分对乙型肝炎相关慢加急性肝功能衰竭患者短期预后的评估价值[J]. 中华实验和临床感染病杂志(电子版), 2022, 16(02): 108-114.
[8] 郑璇, 张宝, 李世龙, 张晓茹. 150例不同基因型慢性乙型肝炎患者逆转录聚合酶区耐药变异位点特征及耐药影响因素[J]. 中华实验和临床感染病杂志(电子版), 2022, 16(02): 82-89.
[9] 钱舒然, 谭婧文, 王萌婕, 张思航, 杨镇英, 何越峰, 李晖. 致癌相关环状RNA在慢性乙型肝炎病毒感染者的表达及临床意义[J]. 中华实验和临床感染病杂志(电子版), 2021, 15(02): 78-85.
[10] 李娜, 王丹. 肾移植受者HCV感染研究进展[J]. 中华移植杂志(电子版), 2023, 17(01): 58-62.
[11] 李娜, 丁小明, 丁晨光, 王丹. 索非布韦联合雷迪帕韦在肾移植HCV感染受者中的应用[J]. 中华移植杂志(电子版), 2022, 16(06): 359-364.
[12] 许语阳, 吕云福, 王葆春. 乙肝后肝硬化门静脉高压症脾肿大外科治疗进展[J]. 中华肝脏外科手术学电子杂志, 2023, 12(04): 469-473.
[13] 李勇, 兰川, 吴斌, 张光年, 李敬东. 术前血小板-白蛋白评分对肝硬化肝癌术后预后的预测价值[J]. 中华肝脏外科手术学电子杂志, 2023, 12(04): 412-416.
[14] 刀辰冉, 陈义发, 阿力木江·买合木提, 徐磊, 陈姚. S指数对符合米兰标准的肝癌合并慢性乙肝患者术后预后的预测价值[J]. 中华肝脏外科手术学电子杂志, 2021, 10(03): 274-278.
[15] 李金璞, 饶向荣. 抗病毒药物和急性肾损伤[J]. 中华肾病研究电子杂志, 2023, 12(05): 287-290.
阅读次数
全文


摘要